Journal article
Influenza antiviral resistance in the Asia-Pacific region during 2011
SK Leang, YM Deng, R Shaw, N Caldwell, P Iannello, N Komadina, P Buchy, M Chittaganpitch, DE Dwyer, P Fagan, AC Gourinat, F Hammill, PF Horwood, QS Huang, PK Ip, L Jennings, A Kesson, T Kok, JL Kool, A Levy Show all
Antiviral Research | Published : 2013
Abstract
Despite greater than 99% of influenza A viruses circulating in the Asia-Pacific region being resistant to the adamantane antiviral drugs in 2011, the large majority of influenza A (>97%) and B strains (∼99%) remained susceptible to the neuraminidase inhibitors oseltamivir and zanamivir. However, compared to the first year of the 2009 pandemic, cases of oseltamivir-resistant A(H1N1)pdm09 viruses with the H275Y neuraminidase mutation increased in 2011, primarily due to an outbreak of oseltamivir-resistant viruses that occurred in Newcastle, as reported in Hurt et al. (2011c, 2012a), where the majority of the resistant viruses were from community patients not being treated with oseltamivir. A s..
View full abstractGrants
Funding Acknowledgements
The authors thank the laboratories and clinicians that submit specimens and isolates to the Melbourne WHO CCRRI. Oseltamivir carboxylate, the active form of the ethyl ester prodrug oseltamivir phosphate, was kindly provided by Hoffmann-La Roche Ltd, Switzerland; zanamivir was kindly provided by GlaxoSmithKline, Australia. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing.